672.94MMarket Cap-2147P/E (TTM)
3.095High2.900Low1.04MVolume3.080Open3.020Pre Close3.10MTurnover0.84%Turnover RatioLossP/E (Static)224.31MShares6.93052wk High1.60P/B370.61MFloat Cap2.21552wk Low--Dividend TTM123.54MShs Float151.800Historical High--Div YieldTTM6.46%Amplitude2.215Historical Low2.983Avg Price1Lot Size
CureVac Stock Forum
at ESMO 2024 Congress
TÜBINGEN, Germany/BOSTON, USA – September 9, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first clinical data from CureVac’s ongoing Phase 1 CVGBM cancer vaccine study in patients with rese...
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study
in Patients with Resected Glioblastoma
·First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
·Part B expected to include up to 20 patients to generate extended data on safety, tolerabil...
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
No comment yet